Cellect Biotechnology's ApoGraft technology demonstrated positive results for orthopedic applications in a study.
Here are three things to know:
1. ApoGraft-treated human fat-derived stem cells significantly improved rotator cuff repair in animals with a shorter incubation compared to traditional adipose-derived stem cells.
2. Prior to this study, ApoGraft was mainly used in hematopoietic applications. Results from a phase 1/2 study of the technology indicated 100 percent engraftment with no reported procedure-related adverse events in 12 patients with hematological malignancies.
3. Israel-based Cellect Biotechnology develops stem cell selection technology for the regenerative medicine market.